Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918940 | 0.84 | HCAR2 (0.39) | HCAR2TAAR1LMNATRPA1LTB4R | |
| SCHEMBL14801981 | 0.82 | HCAR2 (0.40) | HCAR2TAAR1LMNATRPA1LTB4R | |
| SCHEMBL4920321 | 0.78 | LMNA (0.42) | TAAR1LMNATRPA1FFAR1AOC3 | |
| SCHEMBL4918651 | 0.76 | AOC3 (0.40) | LMNAAOC3ADRA2BHTR2AHRH1 | |
| SCHEMBL4916209 | 0.76 | HCAR2 (0.44) | HCAR2TAAR1LMNATRPA1FFAR1 | |
| SCHEMBL96936 | 0.74 | HCAR2 (0.47) | HCAR2TAAR1LMNALTB4RLTB4R2 | |
| SCHEMBL13195347 | 0.74 | HCAR2 (0.47) | HCAR2TAAR1LMNALTB4RLTB4R2 | |
| SCHEMBL8105843 | 0.74 | HCAR2 (0.43) | HCAR2TAAR1LMNATRPA1FFAR1 | |
| SCHEMBL291361 | 0.74 | HCAR2 (0.43) | HCAR2TAAR1LMNATRPA1FFAR1 | |
| SCHEMBL11923788 | 0.74 | HCAR2 (0.47) | HCAR2TAAR1LMNALTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| US-5635508-A | FUNGICIDES | NOVARTIS AG (CH) | 1997-06-03 | — | — | US | disclosed |
| US-5453427-A | Control phytopathogenic fungi especially in monocotelydons, podery mildew and rust | SANDOZ LTD. (CH) | 1995-09-26 | — | — | US | disclosed |
| EP-0634405-A1 | Pyrimidinyl acrylic acid derivatives, process for their preparation and their use for the control of phytopathogens | SANDOZ LTD. (CH) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | HCAR2 2451/4885TAAR1 1504/4885LMNA 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.